535 related articles for article (PubMed ID: 30653440)
1. Statin Toxicity.
Ward NC; Watts GF; Eckel RH
Circ Res; 2019 Jan; 124(2):328-350. PubMed ID: 30653440
[TBL] [Abstract][Full Text] [Related]
2. Statin Intolerance.
Brown AS; Watson KE
Rev Cardiovasc Med; 2018; 19(S1):S9-S19. PubMed ID: 30207553
[TBL] [Abstract][Full Text] [Related]
3. MY APPROACH to Managing Statin-Associated Muscle Symptoms.
Thompson PD
Trends Cardiovasc Med; 2017 Feb; 27(2):160-161. PubMed ID: 28107840
[No Abstract] [Full Text] [Related]
4. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
[TBL] [Abstract][Full Text] [Related]
5. Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
Sivashanmugarajah A; Fulcher J; Sullivan D; Elam M; Jenkins A; Keech A
Intern Med J; 2019 Sep; 49(9):1081-1091. PubMed ID: 31507054
[TBL] [Abstract][Full Text] [Related]
6. Statins: Then and Now.
Toth PP; Banach M
Methodist Debakey Cardiovasc J; 2019; 15(1):23-31. PubMed ID: 31049146
[TBL] [Abstract][Full Text] [Related]
7. Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
Rosenson RS; Baker S; Banach M; Borow KM; Braun LT; Bruckert E; Brunham LR; Catapano AL; Elam MB; Mancini GBJ; Moriarty PM; Morris PB; Muntner P; Ray KK; Stroes ES; Taylor BA; Taylor VH; Watts GF; Thompson PD
J Am Coll Cardiol; 2017 Sep; 70(10):1290-1301. PubMed ID: 28859793
[TBL] [Abstract][Full Text] [Related]
8. Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience.
Ward NC; Pang J; Ryan JDM; Watts GF
Clin Cardiol; 2018 Jan; 41(1):159-165. PubMed ID: 29363784
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of statin therapy.
Adhyaru BB; Jacobson TA
Nat Rev Cardiol; 2018 Dec; 15(12):757-769. PubMed ID: 30375494
[TBL] [Abstract][Full Text] [Related]
10. Update on SAMS: Statin-associated muscle symptoms.
Stock JK
Atherosclerosis; 2018 Feb; 269():260-261. PubMed ID: 29361270
[No Abstract] [Full Text] [Related]
11. Poststatin Lipid Therapeutics: A Review.
Jia X; Lorenz P; Ballantyne CM
Methodist Debakey Cardiovasc J; 2019; 15(1):32-38. PubMed ID: 31049147
[TBL] [Abstract][Full Text] [Related]
12. Sex disparity persists in the prevention of cardiovascular disease in women on statin therapy compared to that in men.
Moreno-Arellano S; Delgado-de-Mendoza J; Santi-Cano MJ
Nutr Metab Cardiovasc Dis; 2018 Aug; 28(8):810-815. PubMed ID: 29754716
[TBL] [Abstract][Full Text] [Related]
13. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS).
Blom DJ; Raal F; Amod A; Naidoo P; Lai YE;
Cardiovasc J Afr; 2019 Jan/Feb 23; 30(1):15-23. PubMed ID: 30720848
[TBL] [Abstract][Full Text] [Related]
14. Statin intolerance - a question of definition.
Algharably EA; Filler I; Rosenfeld S; Grabowski K; Kreutz R
Expert Opin Drug Saf; 2017 Jan; 16(1):55-63. PubMed ID: 27645111
[TBL] [Abstract][Full Text] [Related]
15. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
[TBL] [Abstract][Full Text] [Related]
16. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects.
Li JJ; Liu HH; Wu NQ; Yeo KK; Tan K; Ako J; Krittayaphong R; Tan RS; Aylward PE; Baek SH; Dalal J; Fong AYY; Li YH; O'Brien RC; Lim TSE; Koh SYN; Scherer DJ; Tada H; Kang V; Butters J; Nicholls SJ
Expert Opin Drug Metab Toxicol; 2020 Sep; 16(9):837-851. PubMed ID: 32729743
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Statin Intolerance in Patients With a New Diagnosis of Atherosclerotic Cardiovascular Disease Within a Large Integrated Health Care Institution: The IMPRES Study.
Bair TL; May HT; Knowlton KU; Anderson JL; Lappe DL; Muhlestein JB
J Cardiovasc Pharmacol; 2020 May; 75(5):426-431. PubMed ID: 32079856
[TBL] [Abstract][Full Text] [Related]
18. [Statins and the risk of diabetes].
Simonyi G
Orv Hetil; 2013 Oct; 154(43):1691-5. PubMed ID: 24140507
[TBL] [Abstract][Full Text] [Related]
19. The myopathy of statins.
Smogorzewski M
J Ren Nutr; 2005 Jan; 15(1):87-93. PubMed ID: 15648014
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
Verma S; Leiter LA; Mazer CD; Bain SC; Buse J; Marso S; Nauck M; Zinman B; Bosch-Traberg H; Rasmussen S; Michelsen MM; Bhatt DL
Circulation; 2018 Oct; 138(15):1605-1607. PubMed ID: 30354517
[No Abstract] [Full Text] [Related]
[Next] [New Search]
